Uploaded April 2021 | Updated September 2026, 1 day ago
Jami Taylor discusses how the struggle between financial and moral imperatives plays out within pharmaceutical companies. One case she was personally involved in was JNJ's decision to bring to market the important tuberculosis drug bedaquiline.
Jami Taylor is Vice President for Corporate Affairs at Protagonist Therapeutics, a biopharmaceutical company in California. Previously she worked for a number of years as a Senior Director for Johnson and Johnson, focusing on their global access policies and more generally on their external relations and worldwide partnerships. She has vast knowledge of the pharmaceutical industry and of the political context in which this industry operates. She has been a great champion for global health within the pharmaceutical industry and beyond – serving, among many other roles, on the Board of Directors of Incentives for Global Health, the NGO promoting the Health Impact Fund proposal.
This presentation and discussion took place at Yale University on 13 April 2021. Opinions and statements expressed by event moderators and participants are their own personal views and do not represent the views of the university.
Jami Taylor discusses how the struggle between financial and moral imperatives plays out within pharmaceutical companies. One case she was personally involved in was JNJ's decision to bring to market the important tuberculosis drug bedaquiline.
Jami Taylor is Vice President for Corporate Affairs at Protagonist Therapeutics, a biopharmaceutical company in California. Previously she worked for a number of years as a Senior Director for Johnson and Johnson, focusing on their global access policies and more generally on their external relations and worldwide partnerships. She has vast knowledge of the pharmaceutical industry and of the political context in which this industry operates. She has been a great champion for global health within the pharmaceutical industry and beyond – serving, among many other roles, on the Board of Directors of Incentives for Global Health, the NGO promoting the Health Impact Fund proposal.
This presentation and discussion took place at Yale University on 13 April 2021. Opinions and statements expressed by event moderators and participants are their own personal views and do not represent the views of the university.
